Inhibitec Antibodies, S.L. Cantabrian biotechnology company

Inhibitec Antibodies, S.L. Cantabrian biotechnology company, spin-off of the CSIC and University of Cantabria, has developed a monoclonal antibody for a new therapeutic target. Last week,  it was in Cambridge, within the Idea Spark Program designed by MIT and SODERCAN. 

A significant number of psoriatic patients with severe disease do not respond to existing therapies. A key molecule involved its pathogenic is BAMBI and its inhibition with our specific mAbs (BI0137) prevents skins and articular lesions in preclinical experimental models of psoriasis.

Share the Post:

Related Posts

Se buscan candidatos/as interesados en desarrollar su carrera científica en la empresa Inhibitec Anticuerpos S.L., para cubrir un puesto de doctor. Inhibitec-Anticuerpos S.L. es una...

Inhibitec is selected as finalist in the BIO-Europe Spring Startup Spotlight competition. This exciting competition offers entrepreneurs an affordable opportunity to engage with top-tier investors...

World Lupus Day was celebrated on 10th May. At Inhibitec we were very proud to share our progress on the effects of BAMBI deficiency in...

Scroll to Top